Telemedycyna Polska Past Earnings Performance

Past criteria checks 0/6

Telemedycyna Polska's earnings have been declining at an average annual rate of -56.7%, while the Healthcare industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 5.6% per year.

Key information

-56.7%

Earnings growth rate

-50.3%

EPS growth rate

Healthcare Industry Growth13.7%
Revenue growth rate5.6%
Return on equity-142.3%
Net Margin-40.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Investors Interested In Telemedycyna Polska S.A.'s (WSE:TMP) Earnings

Mar 07
Investors Interested In Telemedycyna Polska S.A.'s (WSE:TMP) Earnings

Is Telemedycyna Polska S.A.'s(WSE:TMP) Recent Stock Performance Tethered To Its Strong Fundamentals?

Feb 25
Is Telemedycyna Polska S.A.'s(WSE:TMP) Recent Stock Performance Tethered To Its Strong Fundamentals?

Revenue & Expenses Breakdown

How Telemedycyna Polska makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:TMP Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246-240
30 Jun 246-140
31 Mar 246-140
31 Dec 236-140
30 Sep 236040
30 Jun 236-140
31 Mar 236-130
31 Dec 226-140
30 Sep 227-130
30 Jun 226030
31 Mar 225030
31 Dec 215030
30 Sep 216030
30 Jun 215030
31 Mar 215030
31 Dec 205020
30 Sep 204020
30 Jun 204020
31 Mar 205030
31 Dec 195030
30 Sep 196030
30 Jun 196-130
31 Mar 196-130
31 Dec 186-130
30 Sep 186-130
30 Jun 186-130
31 Mar 185-120
31 Dec 175020
30 Sep 176020
30 Jun 176020
31 Mar 176020
31 Dec 165020
30 Sep 165020
30 Jun 165020
31 Mar 165020
31 Dec 155020
30 Sep 155020
30 Jun 155020
31 Mar 156020
31 Dec 146020
30 Sep 146020
30 Jun 146020
31 Mar 146020

Quality Earnings: TMP is currently unprofitable.

Growing Profit Margin: TMP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TMP is unprofitable, and losses have increased over the past 5 years at a rate of 56.7% per year.

Accelerating Growth: Unable to compare TMP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TMP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (26.3%).


Return on Equity

High ROE: TMP has a negative Return on Equity (-142.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 09:19
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Telemedycyna Polska S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution